Dr. Thompson is an active clinical researcher whose interests include hematologic or blood cancers (lymphoma, myeloma, leukemia and myelodysplastic syndrome). He is interested in developing new treatments for all cancers, particularly early phase (Phase I and II) molecular biomarker-driven clinical trials. Dr. Thompson is the medical director for the Early Phase Cancer Research Program as well as the Oncology Precision Medicine Program. Dr. Thompson is a member of the American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR). He is currently on the National Cancer Institute (NCI) Lymphoma Steering Committee and is on the Board of Directors at ASCO.
Audun Utengen, MBA
As co-founder and CEO of Symplur since 2010, Audun builds technology products that surface the most important voices in healthcare, including the most overlooked. By extracting insights from Symplur’s Healthcare Social Graph®, Audun and his team are engineering a path to a deeper understanding of healthcare, empowering users to learn from the expertise shared publicly by patients, clinicians, and other stakeholders. Audun has presented at U.S. and European healthcare conferences including Stanford Medicine X, Mayo Clinic Transform Symposium, and Health Datapalooza. His research has been published in academic journals including the BMJ and JAMA Oncology.